Sarepta Therapeutics Inc (SRPT) CEO Christopher Garabedian on Barclays Healthcare Conference - Trans
Sarepta Therapeutics Inc (SRPT) CEO Christopher Garabedian on Barclays Healthcare Conference - Transcript
Sarepta Therapeutics Inc.'s Price Target Was Slashed By 27% -- Time to Panic?
It's been a rough 12 months for Sarepta Therapeutics, and it got even rougher on Monday following a substantial price target cut from a Wall Street firm. Find out whether this price cut is justified and what investors should consider doing next.
Did Researchers Just Discover a Functional Cure for Duchenne Muscular Dystrophy?
Duchenne muscular dystrophy has no cure, and it often kills its victims by their mid-20s. However, a new international study lends hope that a functional cure to this disease could be in the offing.